JP2008524204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524204A5 JP2008524204A5 JP2007546307A JP2007546307A JP2008524204A5 JP 2008524204 A5 JP2008524204 A5 JP 2008524204A5 JP 2007546307 A JP2007546307 A JP 2007546307A JP 2007546307 A JP2007546307 A JP 2007546307A JP 2008524204 A5 JP2008524204 A5 JP 2008524204A5
- Authority
- JP
- Japan
- Prior art keywords
- cefepime
- amikacin
- pharmaceutically acceptable
- acceptable salt
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 10
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229960004821 amikacin Drugs 0.000 claims 8
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 8
- 230000003115 biocidal effect Effects 0.000 claims 8
- 229960002100 cefepime Drugs 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 239000003381 stabilizer Substances 0.000 claims 6
- 239000011261 inert gas Substances 0.000 claims 4
- 238000011049 filling Methods 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229910001873 dinitrogen Inorganic materials 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960000318 kanamycin Drugs 0.000 claims 2
- 229930027917 kanamycin Natural products 0.000 claims 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 2
- 229930182823 kanamycin A Natural products 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000001243 protein synthesis Methods 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- 230000014616 translation Effects 0.000 claims 2
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 claims 1
- 238000012371 Aseptic Filling Methods 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims 1
- 229960001656 amikacin sulfate Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims 1
- 229960005361 cefaclor Drugs 0.000 claims 1
- 229960000927 cefepime hydrochloride Drugs 0.000 claims 1
- 229960004261 cefotaxime Drugs 0.000 claims 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims 1
- 229960004755 ceftriaxone Drugs 0.000 claims 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 1
- 229960001668 cefuroxime Drugs 0.000 claims 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000007 protein synthesis inhibitor Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- -1 β-lactam cephalosporin Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2510DE2004 | 2004-12-17 | ||
| PCT/IN2005/000415 WO2006064516A1 (en) | 2004-12-17 | 2005-12-16 | Antibiotic combinations for providing total solution to the treatment of infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524204A JP2008524204A (ja) | 2008-07-10 |
| JP2008524204A5 true JP2008524204A5 (https=) | 2009-02-12 |
Family
ID=35811679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007546307A Pending JP2008524204A (ja) | 2004-12-17 | 2005-12-16 | 感染の処置に全面的解決を与えるための抗生物質の組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8178501B2 (https=) |
| EP (1) | EP1861110B1 (https=) |
| JP (1) | JP2008524204A (https=) |
| KR (1) | KR100900208B1 (https=) |
| CN (1) | CN101076342A (https=) |
| AU (1) | AU2005315140B2 (https=) |
| BR (1) | BRPI0517200A (https=) |
| CA (1) | CA2591157C (https=) |
| MX (1) | MX2007007235A (https=) |
| NZ (1) | NZ555076A (https=) |
| UA (1) | UA91205C2 (https=) |
| WO (1) | WO2006064516A1 (https=) |
| ZA (1) | ZA200704392B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080227732A1 (en) * | 2005-05-13 | 2008-09-18 | Venus Remedies Limited | Treatment and Control of Severe Infections Including Cystic Fibrosis |
| WO2007086013A1 (en) * | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising of ceftazidime, tazobactam and linezolid |
| WO2007086011A1 (en) * | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising cefepime, tazobactam and linezolid |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| KR20110058887A (ko) * | 2008-09-18 | 2011-06-01 | 마누 차우드하리 | 신규한 단일 유닛 카바페넴 아미노글라이코사이드 제형 |
| RU2391105C1 (ru) * | 2009-01-11 | 2010-06-10 | Игорь Михайлович Борисов | Способ лечения пневмонии |
| MX2013007146A (es) * | 2010-12-23 | 2013-11-01 | Intercell Austria Ag | Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. |
| US9580472B2 (en) | 2011-11-21 | 2017-02-28 | Board Of Regents Of The University Of Nebraska | Anti-microbial peptides and methods of use thereof |
| US10723764B2 (en) | 2011-11-21 | 2020-07-28 | Board Of Regents Of The University Of Nebraska | Anti-microbial peptides and methods of use thereof |
| WO2014122468A1 (en) * | 2013-02-06 | 2014-08-14 | Astrazeneca Ab | Combination therapy for the treatment of nosocomial pneumonia |
| EP3060213B1 (en) * | 2013-10-22 | 2021-10-13 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
| CN106220647A (zh) * | 2016-07-25 | 2016-12-14 | 海南汤臣史克生物科技有限公司 | 一种头孢硫脒化合物及其制剂和制备方法 |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| SG11202101255UA (en) | 2018-08-09 | 2021-03-30 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| GB2595513B (en) * | 2020-05-29 | 2023-03-29 | Act Therapeutics Ltd | Treatment of infections |
| CN111904929B (zh) * | 2020-06-28 | 2023-02-07 | 江苏吴中医药集团有限公司 | 一种硫酸阿米卡星注射液及其制备方法 |
| CN116116308B (zh) * | 2022-12-16 | 2025-10-28 | 上海楼哒物流技术中心 | 一种医用配液机及其配液方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH16771A (en) * | 1978-04-19 | 1984-02-22 | Ciba Geigy Ag | Synergistic mixtures of cepsulodin sodium and an aminoglycoside |
| FR2546406A1 (fr) * | 1983-05-27 | 1984-11-30 | Michaux Jean | Preparation medicale a usage veterinaire, en particulier pour les ulceres linguaux |
| US4775533A (en) * | 1987-02-24 | 1988-10-04 | Erbamont, Inc. | Reconstitution of dry fill cyclophosphamide |
| US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
| CA2101571A1 (en) * | 1992-09-08 | 1994-03-09 | Elizabeth A. Garofalo | Crystalline dihydrate of a cephalosporin dihydrate salt and injectable compositions thereof |
| KR0139235B1 (ko) * | 1994-01-29 | 1998-04-28 | 조세현 | 정형외과용 세멘트 비드조성물 및 그의 제조방법 |
| EP0781294A1 (de) * | 1995-07-17 | 1997-07-02 | Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. | Metallhaltige ribonukleotidpolypeptide |
| US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
| US6765000B2 (en) | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
| US6197776B1 (en) * | 1999-03-17 | 2001-03-06 | Ernest L. Bonner, Jr. | Method for treatment of reactive arthritis or bursitis |
| WO2001034128A2 (en) | 1999-11-08 | 2001-05-17 | Pharmacia & Upjohn Company | Admixture for intravenous administration of linezolid and other antibacterial agents |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| CN1652750A (zh) * | 2002-04-03 | 2005-08-10 | 兰贝克赛实验室有限公司 | 红霉素a及其衍生物的味道掩蔽组合物 |
| JP3976257B2 (ja) * | 2002-09-17 | 2007-09-12 | 栄研化学株式会社 | 蛋白質の安定化方法 |
| US6900184B2 (en) * | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
-
2005
- 2005-12-16 EP EP05850935.7A patent/EP1861110B1/en not_active Expired - Lifetime
- 2005-12-16 JP JP2007546307A patent/JP2008524204A/ja active Pending
- 2005-12-16 US US11/721,837 patent/US8178501B2/en not_active Expired - Fee Related
- 2005-12-16 BR BRPI0517200-4A patent/BRPI0517200A/pt not_active IP Right Cessation
- 2005-12-16 KR KR1020077010656A patent/KR100900208B1/ko not_active Expired - Fee Related
- 2005-12-16 UA UAA200707601A patent/UA91205C2/ru unknown
- 2005-12-16 CA CA2591157A patent/CA2591157C/en not_active Expired - Fee Related
- 2005-12-16 NZ NZ555076A patent/NZ555076A/en not_active IP Right Cessation
- 2005-12-16 MX MX2007007235A patent/MX2007007235A/es active IP Right Grant
- 2005-12-16 WO PCT/IN2005/000415 patent/WO2006064516A1/en not_active Ceased
- 2005-12-16 AU AU2005315140A patent/AU2005315140B2/en not_active Ceased
- 2005-12-16 CN CNA2005800426111A patent/CN101076342A/zh active Pending
-
2007
- 2007-05-29 ZA ZA200704392A patent/ZA200704392B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524204A5 (https=) | ||
| JP2008530082A5 (https=) | ||
| WO2006085337B1 (en) | Parenteral combination therpy for infective conditions with drug resistant bacterium | |
| CN101129381B (zh) | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 | |
| JP2021102652A (ja) | セフトロザン抗生物質組成物 | |
| RU2007124325A (ru) | Композиции для преодоления опосредованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенные для инъекции | |
| US20120238596A1 (en) | Formulations comprising palonosetron | |
| CA2591157C (en) | Antibiotic combinations for providing total solution to the treatment of infections | |
| US20080227732A1 (en) | Treatment and Control of Severe Infections Including Cystic Fibrosis | |
| CA1215647A (en) | Pharmaceutical compositions | |
| Manfredi et al. | Novel pharmaceutical molecules against emerging resistant gram-positive cocci | |
| EP0764031A1 (en) | Injectable formulations containing a desiccant | |
| JP6705348B2 (ja) | 液体製剤、及び、パロノセトロンの安定性を向上する方法 | |
| RU2011115132A (ru) | Новые однократные единичные составы карбапенема и аминогликозида | |
| WO2018055581A1 (en) | Stable injectable composition of oxazolidinone | |
| JP2761005B2 (ja) | セファロスポリン含有注射用組成物 | |
| JPH02279627A (ja) | 抗菌組成物 | |
| AU2014200107B2 (en) | Compositions and methods of treatment comprising ceftaroline | |
| JPS60188318A (ja) | 抗バクテリア組成物 | |
| CN110585201A (zh) | 抗菌剂与β-内酰胺酶抑制剂组合物及其应用 | |
| Manfredi | ANTIMICROBIAL-RESISTANT GRAM-POSITIVE COCCI IN THE THIRD MILLENNIUM: NOVEL PHARMACEUTICAL WEAPONS AND THEIR THERAPEUTIC PERSPECTIVES |